Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | HER2-low as a separate entity for defining HER2 BC and its prognostic and biological significance

Adam Brufsky • 6 Dec 2022
SABCS 2022
Breast Cancer Antibodies Trastuzumab deruxtecan

Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, discusses the ongoing debate on HER2-low as a separate entity for defining HER2 breast cancer and its prognostic and biological significance. Although HER2-low is unlikely to be a separate entity, Dr Brufsky emphasizes that this does not diminish the utility of HER2-low as a biomarker of response to trastuzumab deruxtecan (T-DXd). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adam Brufsky

2:24
Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices
Adam Brufsky • 6 Dec 2022
2:58
ImPrint immune signature in 10,000 early-stage breast cancer from the real-world FLEX database
Adam Brufsky • 7 Dec 2022
1:06
SABCS 2022 highlights
Adam Brufsky • 6 Dec 2022
0:56
Remaining questions on the management of HER2-low breast cancer
Adam Brufsky • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals